Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm's price target on Regeneron to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - d